Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Multiple Myeloma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
Contact: Study coordinator (Hongming Huang, PhD) · hhmmmc@163.com · +8615006281688

Study leads

Hongming Huang, PhD
Study Director
Affiliated Hospital of Nantong University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE2

Houston, United States

Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma

Relapse Multiple Myeloma · Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Madison, United States

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE2

Tucson, United States · Denver, United States

IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia

Relapsed/Refractory Multiple Myeloma · Plasma Cell Leukemia (PCL)

Abroad (travel likely)RecruitingPHASE2

Changchun, China